| SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2 TM Clausen, DR Sandoval, CB Spliid, J Pihl, HR Perrett, CD Painter, ... Cell 183 (4), 1043-1057. e15, 2020 | 1168 | 2020 |
| Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing L Riva, S Yuan, X Yin, L Martin-Sancho, N Matsunaga, L Pache, ... Nature 586 (7827), 113-119, 2020 | 794 | 2020 |
| MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells X Yin, L Riva, Y Pu, L Martin-Sancho, J Kanamune, Y Yamamoto, K Sakai, ... Cell reports 34 (2), 2021 | 401 | 2021 |
| Functional landscape of SARS-CoV-2 cellular restriction L Martin-Sancho, MK Lewinski, L Pache, CA Stoneham, X Yin, ME Becker, ... Molecular cell 81 (12), 2656-2668. e8, 2021 | 206 | 2021 |
| Clofazimine broadly inhibits coronaviruses including SARS-CoV-2 S Yuan, X Yin, X Meng, JFW Chan, ZW Ye, L Riva, L Pache, CCY Chan, ... Nature 593 (7859), 418-423, 2021 | 200 | 2021 |
| A large-scale drug repositioning survey for SARS-CoV-2 antivirals L Riva, S Yuan, X Yin, L Martin-Sancho, N Matsunaga, ... BioRxiv, 2020.04. 16.044016, 2020 | 94 | 2020 |
| SARS-CoV-2 infects human brain organoids causing cell death and loss of synapses that can be rescued by treatment with Sofosbuvir P Mesci, JS de Souza, L Martin-Sancho, A Macia, A Saleh, X Yin, ... PLoS biology 20 (11), e3001845, 2022 | 51 | 2022 |
| Genome‐scale metabolic modeling reveals SARS‐CoV‐2‐induced metabolic changes and antiviral targets K Cheng, L Martin‐Sancho, LR Pal, Y Pu, L Riva, X Yin, S Sinha, NU Nair, ... Molecular systems biology 17 (11), e10260, 2021 | 34 | 2021 |
| MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. Cell Rep 34: 108628 X Yin, L Riva, Y Pu, L Martin-Sancho, J Kanamune, Y Yamamoto, K Sakai, ... | 27 | 2020 |
| Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters S Yuan, X Yin, XZ Meng, J Chan, ZW Ye, L Riva, L Pache, CCY Chan, ... Research square, rs. 3. rs-86169, 2020 | 21 | 2020 |
| The prolyl-tRNA synthetase inhibitor halofuginone inhibits SARS-CoV-2 infection DR Sandoval, TM Clausen, C Nora, AP Cribbs, A Denardo, AE Clark, ... BioRxiv, 2021.03. 22.436522, 2021 | 16 | 2021 |
| Sec61 inhibitor apratoxin S4 potently inhibits SARS-CoV-2 and exhibits broad-spectrum antiviral activity MO Pohl, L Martin-Sancho, R Ratnayake, KM White, L Riva, QY Chen, ... ACS Infectious Diseases 8 (7), 1265-1279, 2022 | 11 | 2022 |
| A large-scale drug repositioning survey for SARS-CoV-2 antivirals. bioRxiv. 2020 L Riva, S Yuan, X Yin, L Martin-Sancho, N Matsunaga, ... Google Scholar][CrossRef][Green Version], 2020 | 8 | 2020 |
| Synthetic lethality-based prediction of anti-SARS-CoV-2 targets LR Pal, K Cheng, NU Nair, L Martin-Sancho, S Sinha, Y Pu, L Riva, X Yin, ... Iscience 25 (5), 2022 | 7 | 2022 |
| Phosphopantetheinylation in the green microalgae Chlamydomonas reinhardtii EC Sonnenschein, Y Pu, J Beld, MD Burkart Journal of Applied Phycology, 2016 | 5 | 2016 |
| A large-scale drug repositioning survey for SARS-CoV-2 antivirals. 2020 L Riva, S Yuan, X Yin, L Martin-Sancho, N Matsunaga, ... Preprint at https://www. biorxiv. org/content/10.1101/2020.04 16, v1, 0 | 5 | |
| Global siRNA Screen Reveals Critical Human Host Factors of SARS-CoV-2 Multicycle Replication X Yin, Y Pu, S Yuan, L Pache, C Churas, S Weston, L Riva, LM Simons, ... bioRxiv, 2024 | 1 | 2024 |
| Author Correction: Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing L Riva, S Yuan, X Yin, L Martin-Sancho, N Matsunaga, L Pache, ... Nature 631 (8019), E3-E3, 2024 | | 2024 |
| Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing (vol 586, pg 113, 2020) L Riva, S Yuan, X Yin, L Martin-Sancho, N Matsunaga, L Pache, ... NATURE, 2024 | | 2024 |
| Non-canonical STAT1 activation drives APC activation and potentiates tumor clearance sunnie Yoh, S Cuadrado, J Tomalka, Y Pu, Y Bykov, A Garcia-Sastre, ... The Journal of Immunology 212 (1_Supplement), 0741_6254-0741_6254, 2024 | | 2024 |
